NEW YORK (GenomeWeb News) – Cellectis Bioresearch today announced a non-exclusive agreement giving it access to Evrogen's fluorescent proteins.
The deal allows Paris-based Cellectis to incorporate the proteins into its own products, expanding its portfolio of genome engineering tools.
Financial and other terms were not disclosed.
Based in Moscow, Evrogen develops technologies for molecular and cell biology.
In a statement, Luc Selig, sales and marketing director for Cellectis, said that the integration matrix, which allows researchers to express a gene of interest, is a "key component" of the company's kits. The deal with Evrogen extends the choice of promoters and tags in these matrices, and as a result Cellectis can offer its clients "a full range of methods to achieve single-phase developments, thus saving valuable time during experiments."